慢性炎症性心肌病患者中氧化的疗效和安全性:多中心随机研究 (HYPIC试验)
Wu He1,2, Guanglin Cui1,2, Juan Chen3
1Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095# Jiefang Ave, Wuhan, 430030, China.
BMC medicine
|August 9, 2025
概括
氧化 (HCQ) 与普得尼索隆 (PDN) 结合,显著改善了 fulminant心肌炎后慢性炎症性心肌病患者的结局. 这种组合疗法证明了心脏功能的增强和减少炎症,具有可接受的安全性.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性炎症性心肌病 (infl-CMP) 是急性心肌炎的后续,特别是 fulminant心肌炎 (FM).
- 氧化 (HCQ) 显示出在这些患者中减轻过度炎症反应的潜力.
研究的目的:
- 评估HCQ与普得尼索隆 (PDN) 结合的疗效和安全性与PDN单一治疗在患有慢性infl-CMP后FM.患者.
- 评估HCQ对心血管结果,心脏功能和炎症标志物的影响.
主要方法:
- 一个多中心的随机试验,涉及50名患有 FM 后慢性 CMP 的患者.
- 患者在12个月内接受HCQ加PDN或PDN单疗.
- 主要结局:心血管事件的组合;次要结局:LVEF,LVIDd,hs-cTnI,NT-proBNP,hs-CRP和ESR的变化.
主要成果:
- 与PDN单疗相比,HCQ加PDN显著降低了初级复合结局 (HR=0.28,95%CI=0.11-0.71).与PDN单疗相比,HCQ加PDN显著降低了初级复合结局 (HR=0.28,95%CI=0.11-0.71).
- 在组合治疗中,LVEF,LVIDd,hs-cTnI,NT-proBNP和hs-CRP水平显著改善.
- 没有报告与药物相关的严重不良事件,16种血细胞因子降低到与健康对照人相比的水平.
结论:
- 十二个月的HCQ与PDN治疗相结合,显著改善了慢性infl-CMP后FM患者的预后和心脏功能.
- 组合疗法有效抑制炎症,并显示出可接受的安全性.
更多相关视频
10:05Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
8.4K
08:00Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
6.2K
相关概念视频
01:29Cardiomyopathy V: Interprofessional Care
33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
48
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
48
01:30Cardiomyopathy II: Dilated Cardiomyopathy
22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
31
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
31
01:14Myocarditis III: Medical Management
16
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
16
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
508
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
508